Sun’s Ranbaxy Buy Out Could Have Implications For Nexium Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy’s ability to launch generic versions of AstraZeneca’s blockbuster Nexium in the U.S. on May 27 was uncertain already. Sun’s proposed $4 billion acquisition of Ranbaxy could further distract the troubled Indian generics firm from achieving that goal.